MDxHealth (MDxHealth) 3-Year EPS without NRI Growth Rate : 26.40% (As of Mar. 2024)

View and export this data going back to 2008. Start your Free Trial

What is MDxHealth 3-Year EPS without NRI Growth Rate?

MDxHealth's EPS without NRI for the three months ended in Mar. 2024 was $-0.31.

During the past 3 years, the average EPS without NRI Growth Rate was 26.40% per year. During the past 5 years, the average EPS without NRI Growth Rate was 25.70% per year. During the past 10 years, the average EPS without NRI Growth Rate was 7.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of MDxHealth was 30.90% per year. The lowest was -34.20% per year. And the median was 13.50% per year.

Competitive Comparison of MDxHealth's 3-Year EPS without NRI Growth Rate

For the Diagnostics & Research subindustry, MDxHealth's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MDxHealth's 3-Year EPS without NRI Growth Rate Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, MDxHealth's 3-Year EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where MDxHealth's 3-Year EPS without NRI Growth Rate falls into.

MDxHealth 3-Year EPS without NRI Growth Rate Calculation

This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

MDxHealth (NAS:MDXH) 3-Year EPS without NRI Growth Rate Explanation

EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.

MDxHealth 3-Year EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of MDxHealth's 3-Year EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

MDxHealth (MDxHealth) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » MDxHealth SA (NAS:MDXH) » Definitions » 3-Year EPS without NRI Growth Rate

Comparable Companies

BIOQ PSNL VNRX PRE ENZ PRPH ACRS BNR DRIO AWH TMO DHR IQV XSWX:LONN IDXX A MTD ICLR ILMN WAT

Traded in Other Exchanges

N/A

Address

Rue d’Abhooz, 31, Cap Business Center, Herstal, Liege, BEL, 4040

Website

https://www.mdxhealth.com

MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA), and Europe.